Baricitinib
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Arteritis, Giant Cell
Conditions
Arteritis, Giant Cell
Trial Timeline
Mar 9, 2017 → Apr 12, 2021
NCT ID
NCT03026504About Baricitinib
Baricitinib is a phase 2 stage product being developed by Eli Lilly for Arteritis, Giant Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT03026504. Target conditions include Arteritis, Giant Cell.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01724580 | Pre-clinical | Completed |
| NCT06797310 | Phase 2 | Recruiting |
| NCT05074420 | Phase 3 | Terminated |
| NCT04517253 | Phase 2/3 | Terminated |
| NCT03921554 | Phase 2 | Completed |
| NCT03773965 | Phase 3 | Recruiting |
| NCT03559270 | Phase 3 | Terminated |
| NCT03026504 | Phase 2 | Completed |
| NCT02263911 | Phase 1 | Completed |
| NCT01870388 | Phase 1 | Completed |
Competing Products
17 competing products in Arteritis, Giant Cell